Related Experiment Video
Updated: Jun 27, 2025
Isolation, Characterization and MicroRNA-based Genetic Modification of Human Dental Follicle Stem Cells
Published on: November 16, 2018
Improved therapeutic effects on vascular intimal hyperplasia by mesenchymal stem cells expressing MIR155HG that
Xiao Bai1,2, Zaiwen Qi3, Chuanliang Cai1
1Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, Jinan, China.
Insights
Long non-coding RNA MIR155HG enhances mesenchymal stem cell therapy for intimal hyperplasia after coronary artery bypass grafting by acting as a ceRNA for miR-205, improving cell function and promoting angiogenesis.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Stem Cell Therapy
Background:
- Coronary artery bypass grafting (CABG) is crucial for coronary heart disease, but intimal hyperplasia (IH) limits its effectiveness.
- Mesenchymal stem cells (MSCs) show potential for IH treatment, yet their efficacy needs improvement.
Purpose of the Study:
- To investigate if lncRNA MIR155HG enhances MSC efficacy in treating IH.
- To elucidate the competing endogenous RNA (ceRNA) role of MIR155HG in this process.
Main Methods:
- Assessed MIR155HG's effect on MSC function and related proteins.
- Utilized HE and Van Gieson staining for IH detection.
- Employed bioinformatics, qRT-PCR, and dual-luciferase reporter assays to study lncRNA-miRNA interactions.
- Conducted apoptosis, Elisa, and tube formation assays to evaluate ceRNA effects on endothelial protection.
Main Results:
- MIR155HG improved MSC viability and migration, enhancing IH treatment.
- MIR155HG functions as a sponge for miR-205.
- The MIR155HG/miR-205 axis promoted MSC function, reduced apoptosis, and induced angiogenesis.
Conclusions:
- MIR155HG significantly enhances MSC-based therapy for IH.
- The therapeutic benefits are attributed to the ceRNA mechanism involving MIR155HG and miR-205.
- This highlights a novel therapeutic strategy for improving CABG outcomes.
Abstract:
Coronary artery bypass grafting (CABG) is an effective treatment for coronary heart disease, with vascular transplantation as the key procedure. Intimal hyperplasia (IH) gradually leads to vascular stenosis, seriously affecting the curative effect of CABG. Mesenchymal stem cells (MSCs) were used to alleviate IH, but the effect was not satisfactory. This work aimed to investigate whether lncRNA MIR155HG could improve the efficacy of MSCs in the treatment of IH and to elucidate the role of the competing endogenous RNA (ceRNA). The effect of MIR155HG on MSCs function was investigated, while the proteins involved were assessed. IH was detected by HE and Van Gieson staining. miRNAs as the target of lncRNA were selected by bioinformatics analysis. qRT-PCR and dual-luciferase reporter assay were performed to verify the binding sites of lncRNA-miRNA. The apoptosis, Elisa and tube formation assay revealed the effect of ceRNA on the endothelial protection of MIR155HG-MSCs. We observed that MIR155HG improved the effect of MSCs on IH by promoting viability and migration. MIR155HG worked as a sponge for miR-205. MIR155HG/miR-205 significantly improved the function of MSCs, avoiding apoptosis and inducing angiogenesis. The improved therapeutic effects of MSCs on IH might be due to the ceRNA role of MIR155HG/miR-205.
